Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2848692 | 1.00 | MAPK1 (0.35) | MAPK1MAOAMAOBCA1CA2 | |
| SCHEMBL2846727 | 0.86 | DAO (0.31) | DAO | |
| SCHEMBL1710519 | 0.86 | DAO (0.31) | DAO | |
| SCHEMBL16295307 | 0.79 | MAPK1 (0.36) | MAPK1 | |
| SCHEMBL16905505 | 0.75 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL9877840 | 0.75 | — | — | |
| SCHEMBL17839935 | 0.72 | — | — | |
| SCHEMBL14787795 | 0.72 | MAOA (0.35) | MAPK1MAOAMAOBDAO | |
| SCHEMBL8009432 | 0.72 | — | — | |
| SCHEMBL544303 | 0.72 | MAOA (0.35) | MAPK1MAOAMAOBDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2890382-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ACTIVITY OF HYPOXIA-INDUCIBLE TRANSCRIPTION FACTOR COMPLEX AND ITS USE FOR TREATMENT OF TUMORS | University Of Southern California (US) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014035484-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ACTIVITY OF HYPOXIA-INDUCIBLE TRANSCRIPTION FACTOR COMPLEX AND ITS USE FOR TREATMENT OF TUMORS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2014-03-06 | — | — | WO | disclosed |
| EP-2152670-B1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-12-25 | — | — | EP | disclosed |
| US-8202885-B2 | Bridged six-membered ring compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100130545-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-05-27 | — | — | US | disclosed |
| EP-2152670-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2010-02-17 | — | — | EP | disclosed |
| WO-2009130679-A1 | BENZIMIDAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-29 | — | — | WO | disclosed |
| WO-2008132679-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-06 | — | — | WO | disclosed |
| EP-1397365-B1 | HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS | NEUROSEARCH AS (DK) | 2005-02-16 | — | — | EP | disclosed |
| US-20040147505-A1 | Novel heteroaryl-diazabicyclo alkanes as cns-modulators | NEUROSEARCH A/S (DK) | 2004-07-29 | — | — | US | disclosed |
| EP-1397365-A1 | NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS | NeuroSearch A/S (DK) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002096911-A1 | NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS | NEUROSEARCH A/S (DK) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147505-A1 | Novel heteroaryl-diazabicyclo alkanes as cns-modulators | CHRNA3, CHRNA5, CHRNA2 | MAPK1 848/4885MAOA 268/4885MAOB 228/4885 |
| US-20100130545-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | CACNA1E, CACNA1B, CACNA1A | MAPK1 3832/4885MAOA 265/4885MAOB 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.